Identification of a novel glutathione conjugate of flutamide in incubations with human liver microsomes

Drug Metabolism and Disposition

Volumn 35, Issue 7, 2007, Pages 1081-1088

  Kang, Ping ^a   Dalvie, Deepak ^a   Smith, Evan ^a   Zhou, Sue ^a   Deese, Alan ^a,b  

^a PFIZER INC   (United States)

^b GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; FLUTAMIDE; GLUTATHIONE;

ARTICLE; DRUG CONJUGATION; DRUG IDENTIFICATION; DRUG STRUCTURE; INCUBATION TIME; LIQUID CHROMATOGRAPHY; LIVER MICROSOME; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TANDEM MASS SPECTROMETRY;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; ARYL HYDROCARBON HYDROXYLASES; BIOTRANSFORMATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 ENZYME SYSTEM; FLUTAMIDE; GLUTATHIONE; HUMANS; LIVER DISEASES; MAGNETIC RESONANCE SPECTROSCOPY; MICROSOMES, LIVER; MIXED FUNCTION OXYGENASES; MOLECULAR STRUCTURE; NADP; RECOMBINANT PROTEINS; TANDEM MASS SPECTROMETRY;

EID: 34250698951     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.107.014860     Document Type: Article

References (30)

1. Berson A, Wolf C, Chachaty C, Fisch C, Fau D, Eugene D, Loeper J, Gauthier JC, et al. (1993) Metabolic activation of the nitroaromatic antiandrogen flutamide by rat and human cytochromes P-450 including forms belonging to the 3A and 1A subfamilies. J Pharmacol Exp Ther 265:366-372.
2. Brogden RN and Clissold SP (1989) Flutamide-a preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in advanced prostatic cancer. Drugs 38:185-203.
3. Buettner GR (1993) The pecking order of free radicals and antioxidants: lipid peroxidation, alpha-tocopherol, and ascorbate. Arch Biochem Biophys 300:535-543.
4. Cetin M, Demirci D, Unal A, Altinbas M, Guven M, and Unluhizarci K (1999) Frequency of flutamide induced hepatotoxicity in patients with prostate carcinoma. Hum Exp Toxicol 18:137-140.
5. Craine L and Raban M (1989) The chemistry of sulfenamides Chem Rev 89:689-712.
6. Fau D, Eugene D, Berson A, Letteron P, Fromenty B, Fisch C, and Pessayre D (1994) Toxicity of the antiandrogen flutamide in isolated rat hepatocytes. J Pharmacol Exp Ther 269:954-962.
7. Gallemann D, Greif A, Eyer A, Wagner H-U, Sonnenbichler J, Sonnenbichler I, Schäfer W, and Buhrow I (1998) Additional pathways of S-conjugate formation during interaction of 4-nitrosophenetole with glutathione. Chem Res Toxicol 11:1411-1422.
8. Goda R, Nagai D, Akiyama Y, Nishikawa K, Ikemoto I, Aizawa Y, Nagata K, and Yamazoe Y (2006) Detection of a new N-oxidized metabolite of flutamide, N-[4-nitro-3-(trifluoromethyl) phenyl]hydroxylamine, in human liver microsomes and urine of prostate cancer patients. Drug Metab Dispos 34:828-835.
9. Gomez JL, DuPont A, Cusan L, Tremblay M, Tremblay M, and Labrie F. (1992) Simultaneous liver and lung toxicity related to the nonsteroidal antiandrogen nilutamide (Anandron): a case report. Am J Med 92:563-566.
10. Hart W and Stricker BH (1989) Flutamide and hepatitis. Ann Intern Med 110:943-944.
11. Horiuchi S, Inoue M, and Morino Y (1978) γ-Glutamyl transpeptidase. Sideness of its active site on renal brush-border membrane. Eur J Biochem 87:429-437.
12. Horvath JJ, Witmer CM, and Witz G (1992) Nephrotoxicity of the 1:1 acrolein-glutathione adduct in the rat. Toxicol Appl Pharmacol 117:200-207.
13. Ichimura E, Hara K, Matsuzaki Y, and Doi M (1999) Improvement of flutamide-induced hepatotoxicity by ursodeoxycholic acid in male rats. Acta Hepatol Jpn 40:227-234.
14. Katchen B and Buxbaum S, (1975) Disposition of a new, nonsteroid, antiandrogen, alpha,alpha, alpha-trifluoro-2-methyl-4′-nitro-m- propionotoluidide (Flutamide), in men following a single oral 200 mg dose. J Clin Endocrinol Metab 41:373-379.
15. Matsuzaki Y, Nagai D, Ichimura E, Goda R, Tomura A, and Doi M (2006) Metabolism and hepatic toxicity of flutamide in cytochrome P450 1A2 knockout SV129 mice. J Gastroenterol 41:231-239.
16. McLeod DG (1993) Antiandrogenic drugs. Cancer 71:1046-1049.
17. Meister A and Tate SS (1976) Glutathione and related γ-glutamyl compounds. Biosynthesis and utilization. Annu Rev Biochem 45:559-604.
18. Mulder GJ, Kadlubar FF, Mays JB, and Hinson JA (1984) Reaction of mutagenic phenacetin metabolites with glutathione and DNA. Possible implications for toxicity. Mol Pharmacol 26 342-347.
19. Nakagawa Y, Koyama M, and Matsumoto M (1999) Flutamide-induced hepatic disorder and serum concentrations of flutamide and its metabolites in patients with prostate cancer. Acta Urol Jpn 45:821-826.
20. Osculati A and Castiglioni C (2006) Fatal liver complications with flutamide. Lancet 367:1140-1141.
21. Samuel K, Yin W, Stearns RA, Tang YS, Chaudhary AG, Jewell JP, Lanza T, Jr. Lin JS, Hagman WK, Evans DC, et al. (2003) Addressing the metabolic activation potential of new leads in drug discovery: a case study using ion trap mass spectrometry and tritium labeling technique. J Mass Spectrom 38:211-221.
22. Schmitt B, Wilt TJ, Schellhammer PF, DeMasi V, Sartor O, Crawford ED, and Bennett CL (2001) Combined androgen blockade with nonsteroidal antiandrogens for advanced prostate cancer: a systematic review. Urology 57:727-732.
23. Schulz M, Schmold A, Donn F, and Becker H (1988) The pharmacokinetics of flutamide and its major metabolites. Eur J Clin Pharmacol 34:633-636.
24. Shet M, McPhaul M, Fisher CW, Stallings NR, and Eastabrook RW (1997) Metabolism of the antiandrogenic drug (flutamide) by human CYP1A2. Drug Metab Dispos 25:1298-1303.
25. Soglia JR, Contillo LG, Kalgutkar AS, Zhao S, Hop CE, Boyd JG, and Cole MJ (2006) A semiquantitative method for the determination of reactive metabolite conjugate levels in vitro utilizing liquid chromatography-tandem mass spectrometry and novel quaternary ammonium glutathione analogues. Chem Res Toxicol 19:480-490.
26. Testa B (1995) Mono-oxygenase catalyzed nitrogen oxidations, in the Metabolism of Drugs and Other Xenobiotics (Testa B and Caldwell J eds) pp 164-202, Academic Press, New York.
27. Tevell A, Lennernas H, Jonsson M, Norlin M, Lennernas B, Bondesson U, and Hedeland M (2006) Flutamide metabolism in four different species in vitro and identification of flutamide metabolites in human patient urine by high performance liquid chromatography/tandem mass spectrometry. Drug Metab Dispos 34:984-992.
28. Watanabe N, Goda R, Irie T, and Yamashita K (2001) In vitro effects of fluoroquinolone anti-bacterial agents on flutamide metabolism in human liver microsomes. Jpn J Clin Pharmacol Ther 32:65-71.
29. Wysowski DK and Fourcroy JL (1996) Flutamide hepatotoxicity. J Urol 155:209-212.
30. Zuo Z, Tam YK, Diakur J, and Wiebe LI (2002) Hydroxypropyl-β -cyclodextrin- flutamide inclusion complex. II. Oral and intravenous pharmacokinetics of flutamide in the rat. J Pharm Pharm Sci 5:292-298.